Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings has reported Current Deferred Revenue over the past 3 years, most recently at $40000.0 for Q4 2022.

  • Quarterly results put Current Deferred Revenue at $40000.0 for Q4 2022, down 91.54% from a year ago — trailing twelve months through Dec 2022 was $40000.0 (down 91.54% YoY), and the annual figure for FY2022 was $40000.0, down 91.54%.
  • Current Deferred Revenue for Q4 2022 was $40000.0 at GeneDx Holdings, down from $2.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for WGSWW hit a ceiling of $3.8 million in Q1 2022 and a floor of $40000.0 in Q4 2022.
  • Median Current Deferred Revenue over the past 3 years was $1.8 million (2020), compared with a mean of $1.9 million.
  • Peak annual rise in Current Deferred Revenue hit 472.82% in 2022, while the deepest fall reached 91.54% in 2022.
  • GeneDx Holdings' Current Deferred Revenue stood at $1.8 million in 2020, then tumbled by 73.72% to $473000.0 in 2021, then crashed by 91.54% to $40000.0 in 2022.
  • The last three reported values for Current Deferred Revenue were $40000.0 (Q4 2022), $2.8 million (Q3 2022), and $3.2 million (Q2 2022) per Business Quant data.